Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ:CDXC) will host a webinar on July 20, 2022, at 11:00 am ET featuring Dr.
ChromaDex (NASDAQ: CDXC) is enhancing awareness of its research at key conferences, including ASN Nutrition 2022, ISSN, and FASEB’s NAD+ Metabolism and Signaling Conference. The company’s CERP™ program has over 250 material transfer agreements with 235 scientists across 182 institutions. During ASN, presentations will cover topics like NAD+ impact on immune function and cognition. ChromaDex’s involvement aims to highlight the importance of nicotinamide riboside, a precursor to NAD+, for healthy aging and athletic performance.
ChromaDex Corp. (NASDAQ: CDXC) has signed a distribution agreement with Sinopharm Xingsha to enhance cross-border sales of Tru Niagen in China. This partnership aims to amplify brand awareness and secure Health Food Registration in the region, as part of their recent Joint Venture. Currently valued at $700 million in annual sales, the NAD+ supplement market in China is projected to exceed $1.5 billion by 2024. Tru Niagen is backed by scientific research and regulatory approvals across various regions, positioning ChromaDex to capitalize on China's aging population.
ChromaDex Corp. (NASDAQ:CDXC) has announced that CEO Rob Fried and CFO Kevin Farr will present at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference on June 15 at 3:45 p.m. Eastern Time. The presentation will be virtual, and the management team will also engage in one-on-one meetings with institutional investors throughout the day. ChromaDex is committed to healthy aging, focusing on research related to nicotinamide adenine dinucleotide (NAD+) and its precursor, nicotinamide riboside (NR), marketed as Niagen®.
ChromaDex Corp. (NASDAQ:CDXC) has partnered with Juvenis to launch its Tru Niagen® supplement in South Korea. Tru Niagen®, a leading Vitamin B3 product, aims to boost NAD+ levels and is recognized for its health benefits. With South Korea projected to see a 23% increase in its elderly population by 2050, the partnership seeks to meet growing demands for health supplements. The product will be available on major platforms including NaverSmartStore and Gmarket. ChromaDex continues to lead research in NAD+ supplementation.
ChromaDex Corp. (NASDAQ:CDXC) will present virtually at the 12th Annual Invitational on June 8, at 4:30 p.m. ET. The event will feature over 200 companies, and ChromaDex's CEO Rob Fried and CFO Kevin Farr will lead the presentation. Additionally, the management team will hold one-on-one meetings with institutional investors throughout the day. Interested parties can find more information and the webcast link on the LD Micro website. ChromaDex is focused on healthy aging and is known for its NAD+ precursor, Niagen®.
ChromaDex Corp. (NASDAQ:CDXC) has announced the establishment of a joint venture, ChromaDex Asia, aimed at distributing its product, Tru Niagen®, in mainland China. The new venture includes partners Crystal Lake Developments, Pioneer Idea Holdings, and Hong Kong Taikuk. Successful commercialization hinges on approval from China's State Administration for Market Regulation, which is critical for health food registration. CEO Rob Fried emphasized this move as a significant milestone in the company’s strategy for the Chinese market, with the JV's formation contingent upon customary closing conditions.
ChromaDex Corp. (NASDAQ:CDXC) reported first-quarter 2022 net sales of $17.3 million, marking an 18% increase year-over-year, primarily driven by a 20% rise in Tru Niagen® sales to $14.9 million. The gross margin decreased to 61.0% from 62.9% due to changes in business mix and increased supply chain costs. Operating expenses rose to $18.3 million, resulting in a net loss of $7.7 million or $(0.11) per share. For 2022, the company anticipates 15-20% revenue growth, with ongoing investment in brand awareness and R&D, despite potential COVID-19 headwinds.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on May 12, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results for the period ending March 31, 2022. The company intends to release these results shortly after market close on the same day. Interested participants should dial in 10 minutes early. A live broadcast and replay of the call will be available on the company's website. ChromaDex specializes in bioscience, focusing on NAD+ research and its flagship product, Niagen.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
